Kairos Ventures
Kairos Ventures is a venture capital firm that invests in, supports, and nourishes the world's leading scientific discoveries, transforming them into viable businesses. The firm focuses on early-stage investments, often during the formative stages of a company, and collaborates closely with top scientists to commercialize their technologies. Kairos Ventures aims to have a significant impact on the world by backing the best scientists, engineers, and entrepreneurs, helping them transform their knowledge and discoveries into successful businesses.
Kairos Ventures
What We Do
Kairos Ventures provides early-stage capital to companies, investing between $150,000 and $20 million depending on the stage of development and capital requirements.
The firm leverages its expertise and extensive network of professionals in legal, finance, marketing, operations, business development, and HR to support early-stage companies, allowing entrepreneurs to focus on innovation.
Adam Bazih, as Entrepreneur in Residence, provides management, marketing, financial, and commercialization expertise to Kairos portfolio companies, enabling them to grow, stabilize, and meet critical milestones.
Geographic Focus
Portfolio
1200 Pharma uses breakthrough medicinal chemistry technology from Caltech and proprietary biomarker-driven assays from UCLA to accelerate pre-clinical drug discovery and clinical approval timelines.
#Biotechnology
3DBio Therapeutics is a clinical-stage regenerative medicine company pioneering custom-engineered, patient-specific, 3D-bioprinted, living tissue implants. Their first investigational product, AuriNovo™, is in a Phase 1/2a clinical trial for ear reconstruction in patients with microtia.
#Regenerative Medicine
Xidas provides a new breed of micro-devices for high-value markets such as telecom, aerospace, manufacturing, and medicine, using a powerful new manufacturing paradigm called Amalga™.
#Industrial Components
Actinia develops technology to detect hard radiation such as gamma rays and X-rays using perovskite-based materials, offering higher sensitivity and lower production costs.
#Radiation Detection
Actuate Therapeutics is developing novel therapeutics targeting Glycogen Synthase Kinase-3β (GSK-3β) for cancer and inflammatory diseases. The company is in clinical stages with several trials underway.
#Pharmaceuticals
Amorphology is leading the revolution in metal manufacturing and material innovation with patented technologies that eliminate the need for time-consuming and expensive machining and post-processing of parts.
#Metal Manufacturing
Key People
Entrepreneur in Residence
Chief Research and Development Officer
Chief Talent Officer